



ACON[®]
Striving for excellence in offering
global healthcare solutions

June 28, 2021

To Whom It May Concern:

Thank you for your interest in the Flowflex SARS-CoV-2 Antigen Rapid Test.

We, ACON Biotech (Hangzhou) Co., Ltd. as the manufacturer of Flowflex SARS-CoV-2 Antigen Rapid Test, hereby declare that ACON are monitoring the emergence of a new strain of SARS-CoV-2 which has become prevalent in the UK, South Africa, Brazil/Japan, India, USA, France, Philippines, Nigeria, Colombia, Russia and other communities. SARS-CoV-2 of B1.1.7 (20I/501Y.V1), B.1.351 (20H/501Y.V2), P.1 (20J/501Y.V3), B.1.617.1, B.1.617.2, B.1.617.3, B.1.618, B.1.525, B.1.427, B.1.429, P.3, B.1.616, B.1.621, A.23.1, AT.1, B.1.526, P.2 have several mutations in the spike protein and a few mutations in the nucleocapsid protein.

There is no obvious difference observed when testing with different nucleocapsid protein recombination antigens basing on these different variants of SARS-CoV-2, so we do not anticipate that these variants will have any effect on test performance.

Sincerely,

ACON Biotech (Hangzhou) Co., Ltd.



ACON BIOTECH (HANGZHOU) CO., LTD.

No.210 Zhenzhong Road, West Lake District, Hangzhou, P.R. China 310030 Tel: +86 571 8777 5528 • Fax: +86 571 8786 3570 • www.aconlabs.com